28 February 2025 - Sarcoma is one of the most aggressive and challenging cancers, with no significant advances in treatment or survival outcomes in over 30 years. It remains the leading cause of cancer-related death in Australians aged 15-29, highlighting the urgent need for breakthrough research.
Today, Omico Australia has launched the MoST/CASP-SARC Initiative - a world-first research project designed to transform sarcoma treatment. This initiative will screen the largest global patient cohort ever studied, using real-world data, biomarker research, and targeted therapies to accelerate progress where it is most needed.
By analysing data from over 1,500 sarcoma patients and expanding to more than 3,000 in the coming years, this research aims to uncover new treatment pathways and improve patient outcomes on a global scale.
Please find the media release attached for more details.
Key Facts:
- 2695 sarcoma diagnoses in Australia were projected by the AIHW In 2024 with no quantifiable advances to treatment options and survival outcomes for over three decades.
- Sarcoma is the leading cause of cancer-related death in Australians aged 15-29. (AIHW, 2025)
- This groundbreaking research project has the potential to change lives by focussing on screening the largest global patient cohort in the world.
- Sarcoma is one of the most challenging and aggressive cancers, affecting our young disproportionately.
- All sarcoma tumour subtypes will be screened in this new undertaking with a view to discovering new treatment options.
About us:
Omico (www.omico.com.au) is a national, independent, not-for-profit organisation leading the use of precision oncology to turn the tide on cancer in Australia. The unique Omico network of researchers, clinicians, hospitals and industry partners is accelerating community access to the latest developments – comprehensive genomic profiling and next-generation treatments. Omico is a nation-wide organisation and is proud that every state and territory is represented by its Members and Participants, as follows: -
· Linear Clinical Research Limited (WA)
§ Central Adelaide Local Health District (SA)
§ Northern Territory of Australia (NT)
§ Department of Health, The State of Tasmania (Tas)
§ Garvan Institute of Medical Research (NSW)
§ The University of Sydney represented by NHMRC Clinical Trials Centre (NSW)
§ The Australian Capital Territory represented by ACT Health (ACT)
§ Metro South Hospital and Health Services, represented by Princess Alexandra Hospital (QLD)
§ Peter MacCallum Cancer Institute (VIC)
Contact details:
Issued on behalf of Omico by Cube.
For more information, visit: www.Omico.com.au (ABN 67 627 640 733)
For Further Information, Contact:
· Professor David Thomas, Chief of Science and Strategy, Omico
Media Enquiries:
Omico
1800 954 350
Cooper Rice-Brading Foundation
Phil Baker [email protected]
(02) 9357 5378